| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
bnormal glucose metabolism, insulin resistance, and obesity were found to be highly prevalent in patients with endometrial cancer and atypical endometrial hyperplasia. Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is associated with insulin resistance and type 2 diabetes. Preoperative metformin treatment significantly reduced PPP2R4 mRNA expression in endometrial cancer tissues and immunohistochemistry showed significantly decreased expression of the PP2A-β subunit. PPP2R4 knockdown reduced cell proliferation and induced apoptosis in HEC265 and HEC1b cells by activating caspases 3/7. Metformin inhibited the growth of endometrial cancer cells in vivo by indirectly down-regulating PP2A-β and PPP2R4. Inhibition of PP2A may become a preventive measure and a therapeutic strategy for endometrial cancer with insulin resistance.
|
